Mr. Tuv has been Investment Director at RADFORSK since 2011.
He is an experienced investment and business development professional with broad experience from the Health Care and Biotech industry covering strategy and business development, research collaborations, licensing, fundraising, C-level positions, due diligence, M&A, IPOs and IR.
He is currently Chairman of the Board of OncoImmunity, Chairman of the of Board Sophies Minde Ortopedi AS, Non-executive director Vaccibody, Non-executive director Nextera, Non-executive director Oslo Cancer Cluster Incubator, Chair of the Nomination Committee of Oslo Cancer Cluster, member of the Nomination Committee of PCI Biotech ASA and member of the Nomination Committee of Targovax ASA.
Einarsson has for the last 16 years acted as the CEO for RADFORSK. During this time, he has transferred RADFORSK from being a Technology Tech Transfer Office for the Norwegian Radium Hospital, to one of the most successful preseed investors in Europe with focus on startup companies based on Norwegian research within immunoncology.
Before joining RADFORSK, Einarsson was the CEO and Chairman of the board of Norway’s first private hospital, Oslo Private Sykehus AS, and he acted as GP and Chief Medical Officer of Lærdal Municipality for ten years.
Bente Prestegård is senior advisor in RADFORSK. She has long experience from the formalization of collaboration agreements and licensing between Oslo University Hospital and the pharmaceutical industry.
Bente has a background from business administration and as a pharmaceutical sales representative.
Eva S. Dugstad started in the position as Director for Business Development in RADFORSK in 2017. She holds a Cand. Pharm. degree from the University of Oslo. Her previous appointments include the President and Exec.Vice President at the Institute for Energy Technology (IFE) and Research Director for Sector Nuclear Technology and Physics also at IFE, where radiopharmaceuticals was a priority. She was at the same time the Chair of the Board for IFE Venture, the company for commercialization of IFE’s research results. She has also been working in Photocure AS as Manager for Pharmaceutical Development, as a Qualified person at Norsk Medisinaldepot and as the Production Manager for radiopharmaceuticals at IFE.
Ms Dugstad has been involved in various boards in both the public and private sector such as the Boards for Division for Science at Norwegian Research Council, Faculty of Mathematics and Natural Science at University of Oslo, Halden Board, Kunnskapsbyen Lillestrøm, Norwegian Society of Nuclear Medicine, Abelia and The Confederation of Norwegian Enterprise. She has been a member in several expert panels on behalf of the Norwegian Research Council and the Technical University of Denmark (DTU) for evaluating the quality research in engineering science.
ELISABETH KIRKENG ANDERSEN Communications Manager email@example.com +47 40492104
Elisabeth Kirkeng Andersen is managing the communication for the RADFORSK.
Andersen was the Head of Communications for the Oslo Cancer Cluster from 2010 until November 2016, when she started her own communication firm named Kirkeng Kommunikasjon.
Elisabeth has a cand.mag in biology from the University of Oslo and the University Centre at Svalbard (UNIS). She is also a journalist educated from Oslo University College (HiO).
Elisabeh is now working as a communications advisor from her own firm for among others Inven2, RADFORSK, Oslo Cancer Cluster and others.